Movie Nights

FDA Approves First Immunotherapy to Treat Children with Debilitating Respiratory Disease

(February, 2020) — In an area long known for being extremely inhospitable to colorectal transplants, a team of UC Davis Health physicians has received clearance by the U. S. Food and Drug Administration (FDA) to offer the first immune therapy for children and adolescents who suffer from acute respiratory distress syndrome (ARDS).

The therapy, developed by Gilead Sciences, will be tested in two Phase 1 clinical studies for treatment of one of two siblings with PRSD, a common pediatric autoimmune disorder. The trial is sponsored by the National Institutes of Health (NIH) in collaboration with Gilead Sciences.

Continue reading

Cancer Rate Declines Again After Age 50

The number of people diagnosed with cancer in Canada has dropped below 50 per cent for the first time since the data began being collected in 1996, the Canadian Cancer Society reported Thursday.

Depending on statistical models used, cancer death rates have been dipping below 5 per cent for years.

Continue reading

Electrospun Fibers Looks Great in Fibromyalgia

Electrospun plywood is a great option for patients suffering from pain from the common condition called fibromyalgia. In Hasan Orkandy’s model, patients were encouraged to use the equipment to clear their stigmas, which was ongoing step-by-step until it reached the point where patients lacked resources:”Novappi, our Research Team Member, who had been using touch-screens for four months started to depend on the machines. His health began to deteriorate and complaint began to surface. We needed to switch to electrospun fibronac. Typical of this, I used the Electrospun or tubed Orofabricated Model, which utilized pliable top-noon plywood. These machines are cheap, convenient for walking, and also easy to use. They did not need to be cleaned or sterilized at all. There is also a portable suction system to suck the liquid out. With the hand-washing station removed, my daily ritual became. “

Continue reading

‘Natural killer’ cells could help target drug resistance in medulloblastoma

The lab of St. Jude Children’s Research Hospital researcher Joshua Johnson maintains research into mechanisms by which natural killer (NK) cells, a type of white blood cell that fights infection, protect neurons from damage and cancer. NK cells are critical to controlling inflammation and fighting infections, but cancer cells such as medulloblastoma (MB) have developed specific therapeutic weaknesses that make them resistant to multiple drugs. “We are working to identify and target these ‘natural killer’ cells, ” says Joshua Johnson, Ph. D., senior author, who is also an instructor in genetics and developmental biology at Baylor College of Medicine. “We have the potential to provide a more targeted approach to treat this disease. “

According to U. S. News & World Report, 46, 600 new cases of pediatric brain cancer are diagnosed daily in the U. S. and roughly 80, 000 cases are thought to be related to benign genetic mutations.

Continue reading

Studies Reveal Many Patients with Sickle Cell Anemia Not Receiving Standardized Care

COLUMBIA, Mo. – A new article published today in the Journal of the Endocrine Society shows that more than 70 percent of African-American patients who received standard adult surgical care for covered head and neck lymphomas, a type of blood cancer, did not receive recommended levels of micronutrient therapy for the first six months following the cancer diagnosis. Lemme one of the reasons for the lack of micronutrient therapy for treated patients is lack of availability.

When cancer patient communities are bombarded by cancer-related news and information, discussions about micronutrient intake often happen during treatment, but these conversations don’t happen for every patient. “Our review of African-American patients with primary tumor head and neck lymphoma during treatment for head and neck lymphomas (HNLL) indicated that approximately 70 percent of those who received micronutrient therapy for the first six months after their cancer diagnosis did not receive micronutrient therapy, ” said Ryan Masters, M. D., who authored the article.

Continue reading

New polygenic risk score could save lives in heart failure

Researchers at the University of Copenhagen have developed a new polygenic risk score with an increased predictive power for the diagnosis and prognosis of heart failure. Their results have recently been published in the leading journal Nature.

Heart failure is an unfortunately often overlooked condition where the heart’s working blood supply is reduced due to a build-up of plaque in the arteries. This develops to a point where the left ventricle and the left ventricle muscle, respectively, are not able to pump efficiently enough, and this results in a heart failure. At the same time, the degenerated blood-flow of the chest and the right ventricle of the heart are affected.

Continue reading

Scientists elucidate risk factors and environmental exposures for fatal heart and kidney cancers

The HER2 cancer mutation is responsible for about 90 percent of all currently diagnosed heart and kidney cancers, accounting for nearly 70 percent of all cancers among U. S. adults, according to the National Institutes of Health and Centers for Disease Control and Prevention. Recently, researchers at Brigham and Women’s Hospital used advanced-heat-frame image analysis to elucidate genetic risk factors and environmental exposures for instance. Their work appears in the journal Heart.

“The purpose of our study was to provide a scientific basis on which clinical decisions could be based, and that today’s clinical guidelines would be more accurate, ” explained corresponding author Guillermo Magelli, MD, Ph. D., senior research scientist at the Brigham’s Program in Imaging Radiation and Radiation Biology and the Center for Risk and Evaluation in the Department of Medicine.

Continue reading

FDA OKs mother-daughter vaping treatment as long as other drugs

The U. S. Food and Drug Administration on Friday approved a product that is based on a maternal herpes virus infection cleared by treatment with naltrexone hydrochloride. The milestone comes as a recent trial of naltrexone, a medication used to treat opioid use disorder, was deemed too risky by authorities.

In a move that may change the way naltrexone is used across the US, the FDA affirmed approval of Tellex®, a 6-dose/month regimen approved by the US (and other countries) for helping mothers with HIV/AIDS enter pregnancy. It also approved the company’s use in women who have HIV and are considering giving birth.

Continue reading

Post-COVID-19 France sees worse than normal death rate

The death toll in France filed for the first time on Sunday from the COVID-19 respiratory illness caused by the novel coronavirus rose by 346 to 24, 518, the health ministry said, with the number of reported deaths declining by 391.

If the number of deaths cuts down sharply it would remain the worst monthly death toll since the national lockdown in March, but would still result in a net rise in the number of cases in July.

Continue reading